Takahide Hoshioka

Musashino Red Cross Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Tomoji Kato

Tokyo Teishin Hospital

Hiroyuki Nakanishi

Musashino Red Cross Hospital

Teiji Kuzuya

Fujita Health University Hospital

Yasuhiro Asahina

Tokyo Medical and Dental University

Namiki Izumi

Musashino Red Cross Hospital

Keisuke Tanaka

Tokyo Medical and Dental University

Masayuki Kurosaki

Musashino Red Cross Hospital

Yuichiro Suzuki

University of Yamanashi

Shinji Tamaki

Nara Medical University

Jun Itakura

Musashino Red Cross Hospital

Cooperative Institutions

Musashino Red Cross Hospital

University of Yamanashi

Yale University

Centers for Disease Control and Prevention

Hepatitis B Foundation

Tokyo Medical and Dental University

The University of Tokyo

The Japanese Society of Gastroenterological Surgery

University of Yamanashi Hospital

Fujita Health University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

Oncology (2011)

Teiji Kuzuya Yasuhiro Asahina Kaoru Tsuchiya Keisuke Tanaka Yuichiro Suzuki

Objectives: The aim of this study was to investigate the relationships between early changes in the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), and antitumor response in the early period following administration of sorafenib in patients with advanced hepatocellular carcinoma (HCC). Methods: Forty-eight advanced HCC patients were evaluated. AFP and DCP were measured at baseline, and after 2 and 4 weeks, and the antitumor responses were evaluated according to the RECIST criteria 4 weeks after starting sorafenib therapy. The ratios of each tumor marker were compared by stratifying the patients into the partial response (PR) + stable disease (SD) group or the progressive disease (PD) group. Results: Both 2 and 4 weeks after starting sorafenib therapy, the AFP ratio in the PR + SD group (n = 32) was significantly lower than in the PD group (n = 16; p = 0.002, p = 0.002). DCP was elevated in both the PR + SD group and the PD group 2 weeks and 4 weeks after starting sorafenib therapy. Conclusions: Evaluation of AFP ratios 2 and 4 weeks after starting sorafenib therapy may be useful for predicting antitumor response. On the other hand, early elevation of DCP does not necessarily suggest treatment failure by sorafenib, as DCP elevation can occur despite therapeutic efficacy.

10.1159/000334454

Cite

Citations (82)

Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

Kanzo (2011)

Teiji Kuzuya Kaoru Tsuchiya Keisuke Tanaka Yuichiro Suzuki Takahide Hoshioka

We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.

Portal vein thrombosis

Liver function

Complete response

Liver Cancer

10.2957/kanzo.52.325

Cite

Citations (0)

Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma

Kanzo (2010)

Teiji Kuzuya Kaoru Tsuchiya Keisuke Tanaka Yuichiro Suzuki Takahide Hoshioka

We investigated changes in tumor markers before and after sorafenib therapy for advanced hepatocellular carcinoma (HCC). Subjects were 28 patients who began sorafenib therapy. HCC stage was III (n=5), IVA (n=10) and IVB (n=13). AFP, AFP-L3 and PIVKA-II were compared before and at one month after sorafenib administration. While no significant changes were observed for AFP and AFP-L3, PIVKA-II increased significantly following treatment (p<0.001). Similar results were observed for investigation of outcomes based on RECIST criteria (PR, n=1; SD, n=18; PD, n=9), with increases also observed for PR or SD patients. PIVKA-II increased following sorafenib administration regardless of therapeutic effects based on imaging findings. The present results are very interesting from the perspective of the clinical effects of sorafenib.

10.2957/kanzo.51.403

Cite

Citations (1)

82 ASSOCIATION BETWEEN IL28B GENE VARIATION AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA AFTER INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C

Journal of Hepatology (2011)

Y. Asahina Kosuke Tanaka Yuhei Suzuki Nobuharu Tamaki Takahide Hoshioka

10.1016/s0168-8278(11)60084-6

Cite

Citations (8)